Tags

Type your tag names separated by a space and hit enter

Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease.
Cell Mol Life Sci. 2018 06; 75(11):2075-2091.CM

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopamine (DA) neurons through apoptotic, inflammatory and oxidative stress mechanisms. The octadecaneuropeptide (ODN) is a diazepam-binding inhibitor (DBI)-derived peptide, expressed by astrocytes, which protects neurons against oxidative cell damages and apoptosis in an in vitro model of PD. The present study reveals that a single intracerebroventricular injection of 10 ng ODN 1 h after the last administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) prevented the degeneration of DA neurons induced by the toxin in the substantia nigra pars compacta of mice, 7 days after treatment. ODN-mediated neuroprotection was associated with a reduction of the number of glial fibrillary acidic protein-positive reactive astrocytes and a strong inhibition of the expression of pro-inflammatory genes such as interleukins 1β and 6, and tumor necrosis factor-α. Moreover, ODN blocked the inhibition of the anti-apoptotic gene Bcl-2, and the stimulation of the pro-apoptotic genes Bax and caspase-3, induced by MPTP in the substantia nigra pars compacta. ODN also decreased or even in some cases abolished MPTP-induced oxidative damages, overproduction of reactive oxygen species and accumulation of lipid oxidation products in DA neurons. Furthermore, DBI knockout mice appeared to be more vulnerable than wild-type animals to MPTP neurotoxicity. Taken together, these results show that the gliopeptide ODN exerts a potent neuroprotective effect against MPTP-induced degeneration of nigrostriatal DA neurons in mice, through mechanisms involving downregulation of neuroinflammatory, oxidative and apoptotic processes. ODN may, thus, reduce neuronal damages in PD and other cerebral injuries involving oxidative neurodegeneration.

Authors+Show Affiliations

Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France. University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia.University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia.University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia.Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France. Behavioral Analysis Platform (SCAC), Normandy University, 76183, Rouen, France.Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France. Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France.Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France. Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France.Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France.Behavioral Analysis Platform (SCAC), Normandy University, 76183, Rouen, France.Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230, Odense M, Denmark.Department of Biochemistry and Molecular Biology, University of Southern Denmark, 5230, Odense M, Denmark.Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France. Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France.Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France.University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia.University Tunis El Manar, Faculty of Science of Tunis, UR/11ES09, Laboratory of Functional Neurophysiology and Pathology, 2092, Tunis, Tunisia. olfa.masmoudi@fst.utm.tn.Laboratory of Neuronal and Neuroendocrine Communication and Differentiation, Institute for Research and Innovation in Biomedicine (IRIB), Normandy University, UNIROUEN, INSERM, U1239, 76821, Mont-Saint-Aignan, France. david.vaudry@univ-rouen.fr. Regional Cell Imaging Platform of Normandy (PRIMACEN), Normandy University, UNIROUEN, INSERM, 76821, Mont-Saint-Aignan, France. david.vaudry@univ-rouen.fr.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29264673

Citation

Bahdoudi, Seyma, et al. "Neuroprotective Effects of the Gliopeptide ODN in an in Vivo Model of Parkinson's Disease." Cellular and Molecular Life Sciences : CMLS, vol. 75, no. 11, 2018, pp. 2075-2091.
Bahdoudi S, Ghouili I, Hmiden M, et al. Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease. Cell Mol Life Sci. 2018;75(11):2075-2091.
Bahdoudi, S., Ghouili, I., Hmiden, M., do Rego, J. L., Lefranc, B., Leprince, J., Chuquet, J., do Rego, J. C., Marcher, A. B., Mandrup, S., Vaudry, H., Tonon, M. C., Amri, M., Masmoudi-Kouki, O., & Vaudry, D. (2018). Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease. Cellular and Molecular Life Sciences : CMLS, 75(11), 2075-2091. https://doi.org/10.1007/s00018-017-2727-2
Bahdoudi S, et al. Neuroprotective Effects of the Gliopeptide ODN in an in Vivo Model of Parkinson's Disease. Cell Mol Life Sci. 2018;75(11):2075-2091. PubMed PMID: 29264673.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Neuroprotective effects of the gliopeptide ODN in an in vivo model of Parkinson's disease. AU - Bahdoudi,Seyma, AU - Ghouili,Ikram, AU - Hmiden,Mansour, AU - do Rego,Jean-Luc, AU - Lefranc,Benjamin, AU - Leprince,Jérôme, AU - Chuquet,Julien, AU - do Rego,Jean-Claude, AU - Marcher,Ann-Britt, AU - Mandrup,Susanne, AU - Vaudry,Hubert, AU - Tonon,Marie-Christine, AU - Amri,Mohamed, AU - Masmoudi-Kouki,Olfa, AU - Vaudry,David, Y1 - 2017/12/20/ PY - 2017/07/07/received PY - 2017/12/05/accepted PY - 2017/11/13/revised PY - 2017/12/22/pubmed PY - 2018/11/14/medline PY - 2017/12/22/entrez KW - Inflammation and oxidative response KW - MPTP KW - Neurodegeneration KW - Neuropeptide ODN KW - Neuroprotection KW - Parkinson’s disease SP - 2075 EP - 2091 JF - Cellular and molecular life sciences : CMLS JO - Cell Mol Life Sci VL - 75 IS - 11 N2 - Parkinson's disease (PD) is a neurodegenerative disorder characterized by a progressive loss of dopamine (DA) neurons through apoptotic, inflammatory and oxidative stress mechanisms. The octadecaneuropeptide (ODN) is a diazepam-binding inhibitor (DBI)-derived peptide, expressed by astrocytes, which protects neurons against oxidative cell damages and apoptosis in an in vitro model of PD. The present study reveals that a single intracerebroventricular injection of 10 ng ODN 1 h after the last administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) prevented the degeneration of DA neurons induced by the toxin in the substantia nigra pars compacta of mice, 7 days after treatment. ODN-mediated neuroprotection was associated with a reduction of the number of glial fibrillary acidic protein-positive reactive astrocytes and a strong inhibition of the expression of pro-inflammatory genes such as interleukins 1β and 6, and tumor necrosis factor-α. Moreover, ODN blocked the inhibition of the anti-apoptotic gene Bcl-2, and the stimulation of the pro-apoptotic genes Bax and caspase-3, induced by MPTP in the substantia nigra pars compacta. ODN also decreased or even in some cases abolished MPTP-induced oxidative damages, overproduction of reactive oxygen species and accumulation of lipid oxidation products in DA neurons. Furthermore, DBI knockout mice appeared to be more vulnerable than wild-type animals to MPTP neurotoxicity. Taken together, these results show that the gliopeptide ODN exerts a potent neuroprotective effect against MPTP-induced degeneration of nigrostriatal DA neurons in mice, through mechanisms involving downregulation of neuroinflammatory, oxidative and apoptotic processes. ODN may, thus, reduce neuronal damages in PD and other cerebral injuries involving oxidative neurodegeneration. SN - 1420-9071 UR - https://www.unboundmedicine.com/medline/citation/29264673/Neuroprotective_effects_of_the_gliopeptide_ODN_in_an_in_vivo_model_of_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -